FY2024 EPS Forecast for Pacira BioSciences Raised by Analyst

Pacira BioSciences, Inc. (NASDAQ:PCRX) – Stock analysts at Zacks Research boosted their FY2024 EPS estimates for shares of Pacira BioSciences in a note issued to investors on Wednesday, December 11th. Zacks Research analyst R. Department now expects that the company will earn $2.60 per share for the year, up from their prior forecast of $2.36. The consensus estimate for Pacira BioSciences’ current full-year earnings is $2.28 per share. Zacks Research also issued estimates for Pacira BioSciences’ Q2 2025 earnings at $0.58 EPS, FY2025 earnings at $2.30 EPS, Q1 2026 earnings at $0.61 EPS and FY2026 earnings at $2.64 EPS.

Several other research analysts have also weighed in on PCRX. Royal Bank of Canada boosted their price target on Pacira BioSciences from $15.00 to $16.00 and gave the stock a “sector perform” rating in a research report on Thursday, November 7th. Jefferies Financial Group raised their target price on shares of Pacira BioSciences from $15.00 to $18.00 and gave the company a “buy” rating in a research note on Tuesday, September 24th. HC Wainwright reaffirmed a “buy” rating and set a $39.00 price target on shares of Pacira BioSciences in a research report on Wednesday, December 4th. Barclays cut their price target on shares of Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating for the company in a research note on Tuesday, November 12th. Finally, Needham & Company LLC restated a “buy” rating and set a $22.00 price objective on shares of Pacira BioSciences in a research note on Friday, November 8th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, Pacira BioSciences presently has a consensus rating of “Hold” and a consensus price target of $23.50.

Pacira BioSciences Price Performance

NASDAQ:PCRX opened at $19.86 on Monday. Pacira BioSciences has a 52-week low of $11.16 and a 52-week high of $35.95. The company has a market cap of $916.94 million, a P/E ratio of -9.78 and a beta of 0.80. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25. The stock’s 50-day simple moving average is $17.27 and its 200 day simple moving average is $19.04.

Institutional Trading of Pacira BioSciences

Hedge funds and other institutional investors have recently modified their holdings of the stock. Outfitter Financial LLC boosted its holdings in shares of Pacira BioSciences by 5.7% during the second quarter. Outfitter Financial LLC now owns 20,190 shares of the company’s stock worth $578,000 after acquiring an additional 1,095 shares during the period. The Manufacturers Life Insurance Company boosted its stake in Pacira BioSciences by 6.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 23,932 shares of the company’s stock valued at $685,000 after purchasing an additional 1,354 shares during the period. nVerses Capital LLC grew its holdings in Pacira BioSciences by 800.0% in the 2nd quarter. nVerses Capital LLC now owns 1,800 shares of the company’s stock valued at $51,000 after buying an additional 1,600 shares in the last quarter. Innealta Capital LLC acquired a new position in Pacira BioSciences in the 2nd quarter valued at $50,000. Finally, Bank of New York Mellon Corp increased its position in Pacira BioSciences by 0.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 400,002 shares of the company’s stock worth $11,444,000 after buying an additional 2,141 shares during the period. Institutional investors own 99.73% of the company’s stock.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.